Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.
Novo Nordisk acquires Embark Biotech in deal worth over €470m pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Embark Laboratories: Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a.
Novo Nordisk Acquires CBMR Spinout for Obesity, Diabetes Treatment miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.